PE20181895A1 - Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer - Google Patents
Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancerInfo
- Publication number
- PE20181895A1 PE20181895A1 PE2018001829A PE2018001829A PE20181895A1 PE 20181895 A1 PE20181895 A1 PE 20181895A1 PE 2018001829 A PE2018001829 A PE 2018001829A PE 2018001829 A PE2018001829 A PE 2018001829A PE 20181895 A1 PE20181895 A1 PE 20181895A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- cinnolin
- amine compounds
- cancer
- hydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a compuestos cinnolin-4-amina sustituidas de formula (I) y sus sales farmaceuticamente aceptables; en donde R1 es alquilo (C1-C3); R2 es hidro o alquilo (C1-C3); o R1 y R2 junto al N pueden formar un azetidino, pirrolidino o piperidinilo; y R3 es hidro o metilo. Estos compuestos modulan selectivamente la cinasa de ataxia telangiectasia mutada (ATM cinasa), incluyendo el cancer. Un compuesto seleccionado es: 6-[6-(3-dimetilaminopropoxi)piridin-3-il]-N-metil-4-[[(1S)-1-(oxan-4-il)etil]amino]cinnolin-3-carboxamida. Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos y sales de los mismos; intermedios utiles en la fabricacion de dichos compuestos y metodos para tratar una enfermedad mediada por ATM incluyendo el cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662310883P | 2016-03-21 | 2016-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181895A1 true PE20181895A1 (es) | 2018-12-11 |
Family
ID=58361025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001829A PE20181895A1 (es) | 2016-03-21 | 2017-03-20 | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US20190099421A1 (es) |
EP (1) | EP3433251A1 (es) |
JP (1) | JP2019512512A (es) |
KR (1) | KR20180127419A (es) |
CN (1) | CN108884084A (es) |
AR (1) | AR107937A1 (es) |
AU (1) | AU2017237394A1 (es) |
BR (1) | BR112018068347A2 (es) |
CA (1) | CA3017035A1 (es) |
CO (1) | CO2018010951A2 (es) |
DO (1) | DOP2018000197A (es) |
IL (1) | IL261648A (es) |
MA (1) | MA43733A (es) |
MX (1) | MX2018011283A (es) |
PE (1) | PE20181895A1 (es) |
SG (1) | SG11201806982PA (es) |
TW (1) | TW201808939A (es) |
WO (1) | WO2017162605A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
RU2020133020A (ru) * | 2018-03-14 | 2022-04-14 | Мерк Патент Гмбх | Соединения и их применения для лечения опухолей у субъекта |
KR20210061337A (ko) * | 2018-09-14 | 2021-05-27 | 수저우 잔롱 파마 리미티드 | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 |
JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatm阻害剤との組合わせ |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PT880508E (pt) | 1996-02-13 | 2003-07-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
JP2014506878A (ja) | 2011-01-28 | 2014-03-20 | ノバルティス アーゲー | Cdk9阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用 |
BR112013030095A2 (pt) * | 2011-05-23 | 2019-09-24 | Elan Pharm Inc | inibidores de atividade de lrrk2 cinase |
NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/en not_active Withdrawn
- 2017-03-20 CA CA3017035A patent/CA3017035A1/en not_active Abandoned
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/en active Application Filing
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko unknown
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL261648A (en) | 2018-10-31 |
AR107937A1 (es) | 2018-06-28 |
TW201808939A (zh) | 2018-03-16 |
JP2019512512A (ja) | 2019-05-16 |
MX2018011283A (es) | 2019-05-27 |
MA43733A (fr) | 2018-11-28 |
US20190099421A1 (en) | 2019-04-04 |
KR20180127419A (ko) | 2018-11-28 |
SG11201806982PA (en) | 2018-09-27 |
DOP2018000197A (es) | 2018-10-15 |
EP3433251A1 (en) | 2019-01-30 |
CO2018010951A2 (es) | 2018-10-22 |
WO2017162605A1 (en) | 2017-09-28 |
CN108884084A (zh) | 2018-11-23 |
BR112018068347A2 (pt) | 2019-01-15 |
CA3017035A1 (en) | 2017-09-28 |
AU2017237394A1 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
PE20181895A1 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
PE20191486A1 (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER | |
AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |